Nanopro 1000 Nanopro 1000 Nanopro 1000 Nanopro 1000

  • Slides: 65
Download presentation

培� 日程 Nanopro 1000 技�原理介� Nanopro 1000 �器概� Nanopro 1000�� Nanopro 1000的�用 Nanopro 1000��操作

培� 日程 Nanopro 1000 技�原理介� Nanopro 1000 �器概� Nanopro 1000�� Nanopro 1000的�用 Nanopro 1000��操作 Compass �件使用培� Nanopro 1000���化 1

�部:美国硅谷 六家�新蛋白�研究公司�成 • • • Cell Biosciences Nanopro+Wes Alpha Innotech Images system Convergent Bioscience

�部:美国硅谷 六家�新蛋白�研究公司�成 • • • Cell Biosciences Nanopro+Wes Alpha Innotech Images system Convergent Bioscience i. CIEF system Brightwell Technologies Protein Aggregation Zephyrus Single-cell western Cy. Vek Microfluid Immunoassay 2011年 7月更名Protein. Simple 2014年Bio-Techne (NASDAQ: TECH)

Nanopro 1000基本 作原理 3

Nanopro 1000基本 作原理 3

Nanopro 1000�� 蛋白� Isoforms 蛋白�翻�后修�( PTM) isoforms 蛋白� 不同isoforms形成 pattern/profiling 5

Nanopro 1000�� 蛋白� Isoforms 蛋白�翻�后修�( PTM) isoforms 蛋白� 不同isoforms形成 pattern/profiling 5

蛋白质PTM结果解读方式改变 pp. ERK 2 处理后 ERK 1 88% Phospho ERK 2 87% Phospho 处理前

蛋白质PTM结果解读方式改变 pp. ERK 2 处理后 ERK 1 88% Phospho ERK 2 87% Phospho 处理前 ERK 1 7% Phospho ERK 2 8% Phospho pp. ERK 1 4 5 p. ERK 2 6 p. I * He. La 细胞对 EGF 处理的反应 ERK 2 7 8

Nanopro 1000 � 器概� 10

Nanopro 1000 � 器概� 10

Nanopro 1000 � 器概� 11

Nanopro 1000 � 器概� 11

Nanopro 1000 � 器概� 12

Nanopro 1000 � 器概� 12

Nanopro 1000 � 器概� 13

Nanopro 1000 � 器概� 13

Nanopro 1000 � 器概� 14

Nanopro 1000 � 器概� 14

Nanopro 1000 � 器概� 15

Nanopro 1000 � 器概� 15

Nanopro 1000 � 器概� 16

Nanopro 1000 � 器概� 16

Nanopro 1000 � 器概� 17

Nanopro 1000 � 器概� 17

Nanopro 1000�� 18

Nanopro 1000�� 18

Nanopro 1000基��� 盒 ● 基��� 盒 XDR Charge Separation Master Kit For Peggy Sue,

Nanopro 1000基��� 盒 ● 基��� 盒 XDR Charge Separation Master Kit For Peggy Sue, Peggy or Nano. Pro 1000 ��盒会根据需要�行更新,���前和 Protein. Simple�售人�确� 19

举例2:AKT 1磷酸化组合pattern

举例2:AKT 1磷酸化组合pattern

蛋白� isoform pattern与Biological response 32

蛋白� isoform pattern与Biological response 32

33

33

responding patient (#104) with marrow complete response nonresponder (#111) whose disease progressed on treatment

responding patient (#104) with marrow complete response nonresponder (#111) whose disease progressed on treatment 42

蛋白� PTM profiling与疾病 43

蛋白� PTM profiling与疾病 43

蛋白� PTM profiling与疾病 44

蛋白� PTM profiling与疾病 44

nature protocols | VOL. 10 NO. 1 | 2015 | 149

nature protocols | VOL. 10 NO. 1 | 2015 | 149

nature protocols | VOL. 10 NO. 1 | 2015 | 149

nature protocols | VOL. 10 NO. 1 | 2015 | 149

patient-derived CML CD 34+CD 38+ committed progenitor cells (treated for 24 h with drug)

patient-derived CML CD 34+CD 38+ committed progenitor cells (treated for 24 h with drug) 造血祖�胞 clinical CML CD 34+CD 38− primitive progenitor cells 原始祖�胞 Dasatinib,DAS,达沙替尼 Imatinib ,IM,伊�替尼 p-Crk. L peaks Chemiluminescence data for DAS and IM drug

Establishment of Namalwa cell lines stably expressing s. M-CSF and m. M-CSF 建立� 定表达膜型M-CSF和分泌型M-CSFBurkitt‘s淋巴瘤�

Establishment of Namalwa cell lines stably expressing s. M-CSF and m. M-CSF 建立� 定表达膜型M-CSF和分泌型M-CSFBurkitt‘s淋巴瘤� 胞 系

LCM 切片中PTM isoform检测 LCM Samples WT K-RAS Anti-ERK 1/2 4. 5 5 5. 5

LCM 切片中PTM isoform检测 LCM Samples WT K-RAS Anti-ERK 1/2 4. 5 5 5. 5 6 6. 5 Anti-ERK 1/2 200个�瘤� 胞 4. 5 mutant K-RAS 5 5. 5 6 6. 5 KRAS mutations result in elevated levels of the activated, duallyphosphorylated ERK 2 isoform 激光捕获显微切割样本(LCM) Nano proteomic analysis of extracellular receptor kinase-1/2 posttranslational activation in microdissected human hyperplastic colon lesions Proteomics,2012

��� 化 参考:Charge Assay Development v 3 55

��� 化 参考:Charge Assay Development v 3 55

p. I peak 确� 已有文献参考 CST网站数据�: https: //www. cellsignal. com/common/content. jsp? id=phositeplus 63

p. I peak 确� 已有文献参考 CST网站数据�: https: //www. cellsignal. com/common/content. jsp? id=phositeplus 63